feed,title,long_url,short_url
SeekingAlpha,ResMed shares fall 6% despite reporting FQ1 2023 revenue growth,https://seekingalpha.com/news/3897449,
SeekingAlpha,Y-mAbs fails to win FDA AdCom backing for neuroblastoma therapy,https://seekingalpha.com/news/3897448,
